Spots Global Cancer Trial Database for Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer

Official Title: Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.

Study ID: NCT00858520

Conditions

Chronic Obstructive Pulmonary Disease

Lung Cancer

Interventions

Study Description

Brief Summary: A biobank of Serum, plasma, DNA samples together with clinical information including specific questionnaires, complete pulmonary function and chest CT-scan, is prospectively collected in patients seen at the investigators' clinical service. The objective is to study candidate gene pathways in COPD and or lung cancer and to associate them with the clinical characteristics and phenotypes of COPD/emphysema and lung cancer. In subgroups of well characterised patients, other biological materials are also collected (lung tissue biopsies, peripheral blood mononuclear cells).

Detailed Description: All patients with a smoking history of at least 15 pack years, an minimal age of 50 years and an recent available CT scan are enrolled. All subjects with a diagnosis of lung cancer are also collected (irrespective of age and smoking behavior). In addition the investigators collect: * specific questionnaires (MRC, CCQ and smoking history) * medical and professional history * complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity) * serum, plasma and DNA samples. In specific subgroups the investigators also collect: * Peripheral blood mononuclear cells * Lung tissue - if available - from a surgical procedure (lung transplantation or lobectomy)